Parkinson's Disease Mild Cognitive Impairment with MRI evidence of Cholinergic Nucleus 4 Degeneration: A New Subtype?

Area of Science:

• Neuroscience
• Neurology
• Medical Imaging

Background:

• Subtyping Parkinson's disease with mild cognitive impairment (PD-MCI) is crucial for targeted therapies and clinical trial stratification.
• The cholinergic nucleus 4 (Ch4) is implicated in cognitive function and its degeneration correlates with cognitive decline in Parkinson's disease (PD).

Purpose of the Study:

• To investigate if PD-MCI patients with MRI-detected Ch4 degeneration exhibit unique clinical characteristics and cognitive progression.
• To identify a distinct PD-MCI subtype based on Ch4 grey matter density (GMD).

Main Methods:

• Analysis of baseline MRI scans from 148 PD-MCI participants in the Parkinson's Progression Markers Initiative (PPMI) cohort.
• Quantification of Ch4 grey matter density (GMD) to identify patients with degeneration.
• Comparison of clinical profiles and cognitive trajectories between PD-MCI patients with low vs. normal Ch4 GMD.

Main Results:

• PD-MCI patients with low Ch4 GMD presented with more severe motor, autonomic, and olfactory symptoms.
• A significantly higher proportion of patients with low Ch4 GMD belonged to the diffuse malignant PD subtype (51.6% vs. 23.4%, P < 0.01).
• Low Ch4 GMD was associated with a faster progression to cognitive milestones (P = 0.0046).

Conclusions:

• PD-MCI with low Ch4 GMD represents a distinct subtype characterized by more severe symptomatology and accelerated cognitive decline.
• This subtype warrants specific consideration in PD-MCI clinical trials, especially those evaluating cholinergic interventions.